BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
Company Details
- Employees
- 150
- Address
- Sölvegatan 41, Lund,skåne 223 62,sweden
- Industry
- Biotechnology
- Website
- bioinvent.com
- HQ
- Lund, Skåne
Bioinvent International Ab Questions
Bioinvent International Ab's website is bioinvent.com
Bioinvent International Ab's LinkedIn profile is https://se.linkedin.com/company/bioinvent-international-ab
Bioinvent International Ab has
150 employees.
View email and phone details for 150
employees at Bioinvent International Ab.
Bioinvent International Ab's industry is
Biotechnology
Bioinvent International Ab's top competitors are
Polypeptide Group,
Alligator Bioscience Ab,
Sever Pharma Solutions,
Camurus,
Svar Life Science Ab,
Bioglan Ab,
Rechon Life Science Ab,
Immunovia Ab,
Hansa Biopharma,
Biogaia Ab.
Bioinvent International Ab's categories are Biotechnology
